1. Sparreboom. A., Chen. H., Acharya. MR., Senderowicz. AM., Messmann. RA., Kuwabara. T., Venzon. DJ., Murgo. AJ., Headlee. D., Sausville. EA., and Figg. WD., Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine., Clin Cancer Res., 10, 6840-6 (2004)
2. Sausville. EA., Arbuck. SG., Messmann. R., Headlee. D., Bauer. KS., Lush. RM., Murgo. A., Figg. WD., Lahusen. T., Jaken. S., Jing. X., Roberge. M., Fuse. E., Kuwabara. T., and Senderowicz. AM., Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms., J Clin Oncol., 19, 2319-33 (2001) 3. Takahashi. I., Kobayashi. E., Asano. K., Yoshida. M., and Nakano, H., UCN-01, a
selective inhibitor of protein kinase C from Streptomyces., J Antibiot (Tokyo)., 40, 1782-4 (1987)
4. Seynaeve. CM., Stetler-Stevenson. M., Sebers. S., Kaur, G., Sausville. EA., and Worland. PJ., Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells., Cancer Res., 53, 2081-6 (1993)
5. Kawakami. K., Futami. H., Takahara. J., and Yamaguchi. K., UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line., Biochem Biophys Res Commun., 219, 778-83 (1996)
6. Shankar. SL., Krupski. M., Parashar. B., Okwuaka. C., O'Guin. K., Mani. S, and Shafit-Zagardo. B., UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines., J Neurochem., 90, 702-11 (2004)
7. Akinaga. S., Nomura. K., Gomi. K., and Okabe. M., Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C., Cancer Chemother Pharmacol., 32, 183-9 (1993)
8. Akinaga. S., Nomura. K., Gomi. K., and Okabe. M., Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents., Pro Am Assoc Cancer Res., 33, 3072 (1992)
9. Bunch. RT., and Eastman. A., Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor., Clin Cancer Res., 2,
791-7 (1996)
10. Fuse. E., Tanii. H., Kurata. N., Kobayashi. H., Shimada. Y., Tamura. T., Sasaki. Y., Tanigawara. Y., Lush. RD., Headlee. D., Figg. WD., Arbuck. SG., Senderowicz. AM., Sausville. EA., Akinaga. S., Kuwabara. T., and Kobayashi. S., Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein., Cancer Res., 58, 3248-53 (1998)
11. Israili. ZH., and Dayton. PG., Human alpha-1-glycoprotein and its interactions with drugs., Drug Metab Rev., 33, 161-235 (2001)
12. Jacobsen. J., and Brodersen. R., Albumin-bilirubin binding mechanism., J Biol Chem., 258, 6319-26 (1983)
13. Schmid. K., Nimerg. R. B., Kimura. A., Yamaguchi. H., and Binette. JP., The carbohydrate units of human plasma alpha1-acid glycoprotein., Biochim Biophys Acta., 492, 291-302 (1977)
14. Aubert. JP., and Loucheux-Lefebvre. MH., Conformational study of alpha1-acid glycoprotein., Arch Biochem Biophys., 175, 400-9 (1976)
15. Rojo-Dominguez. A., and Hernandez-Arana. A., Three-dimensional modeling of the protein moiety of human alpha1-acid glycoprotein, a lipocalin-family member., Protein Seq Data Anal., 5, 349-355 (1993)
16. Dente. L., Ciliberto. G., and Cortese. R., Structure of the human alpha 1-acid glycoprotein gene: sequence homology with other human acute phase protein genes., Nucleic Acids Res., 13, 3941-52 (1985)
17. Dente. L., Pizza. MG., Metspalu. A., and Cortese. R., Structure and expression of the genes coding for human alpha 1-acid glycoprotein., EMBO J., 6, 2289-96 (1987)
18. Merritt. CM., and Board. PG., Structure and characterisation of a duplicated human alpha 1 acid glycoprotein gene., Gene., 66, 97-106 (1988)
19. Hochepied. T., Berger. FG., Baumann. H., and Libert. C., Alpha(1)-acid glycoprotein:
an acute phase protein with inflammatory and immunomodulating properties., Cytokine Growth Factor Rev., 14, 25-34 (2003)
20. Cheresh. DA., Haynes. DH., and Distasio. JA., Interaction of an acute phase reactant, alpha 1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression., Immunology., 51, 541-8 (1984)
21. Morita. K., and Yamaji. A., Changes in the serum protein binding of vancomycin in
patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels., Ther Drug Monit., 17, 107-12 (1995)
22. Mackiewicz. A., and Mackiewicz. K., Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer., Glycoconj J., 12, 241-7 (1995)
23. Holladay. JW., Dewey. MJ., Michniak. BB., Wiltshire. H., Halberg. DL., Weigl. P., Liang. Z., Halifax. K., Lindup. WE., and Back. DJ., Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir., Drug Metab Dispos., 29, 299-303 (2001)
24. Gambacorti-Passerini. C., Zucchetti. M., Russo. D., Frapolli. R., Verga. M., Bungaro. S., Tornaghi. L., Rossi. F., Pioltelli. P., Pogliani. E., Alberti. D., Corneo. G., and D'Incalci.
M., Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients., Clin Cancer Res., 9, 625-32 (2003)
25. Duche. JC., Urien. S., Simon. N., Malaurie. E., Monnet. I., and Barre. J., Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer., Clin Biochem ., 33, 197-202 (2000)
26. Bailey. DN., and Briggs. JR., The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro., Ther Drug Monit., 26, 40-3 (2004)
27. Nakai. D., Kumamoto. K., Sakikawa. C., Kosaka. T., and Tokui. T., Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method., J Pharm Sci., 93, 847-54 (2004)
28. Kute. T., and Westphal. U., Steroid-protein interactions. XXXIV. Chemical modification of alpha1-acid glycoprotein for characterization of the progesterone binding site., Biochim Biophys Acta., 420, 195-213 (1976)
29. Haughey. DB., Steinberg. I., and Lee. MH., Protein binding of disopyramide displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein., J Pharm Pharmacol., 37, 285-8 (1985)
30. Miyoshi. T., Yamamichi. R., Maruyama. T., and Otagiri. M., Reversal of signs of induced cotton effects of dicumarol-alpha 1-acid glycoprotein systems by phenothiazine neuroleptics through ternary complexation., Pharm Res., 9, 845-9 (1992)
31. Curry. S., Mandelkow. H., Brick. P., and Franks. N., Crystal structure of human serum
albumin complexed with fatty acid reveals an asymmetric distribution of binding sites., Nat Struct Biol., 5, 827-35 (1998)
32. Heine. A., Luz. JG., Wong. CH., and Wilson. IA., Analysis of the class I aldolase binding site architecture based on the crystal structure of 2-deoxyribose-5-phosphate aldolase at 0.99A resolution., J Mol Biol., 343, 1019-34 (2004)
33. Zhu. M., Shao. F., Innes. RW., Dixon. JE., and Xu. Z., The crystal structure of Pseudomonas avirulence protein AvrPphB: a papain-like fold with a distinct substrate-binding site., Proc Natl Acad Sci USA., 101, 302-7 (2004)
34. Hatanaka. Y., and Sadakane. Y., Photoaffinity labeling in drug discovery and developments: chemical gateway for entering proteomic frontier., Curr Top Med Chem., 2, 271-88 (2002)
35. Chang. SH., and Low. PS., Identification of a critical ankyrin-binding loop on the cytoplasmic domain of erythrocyte membrane band 3 by crystal structure analysis and site-directed mutagenesis., J Biol Chem., 278, 6879-84 (2003)
36. Smethurst. PA., Joutsi-Korhonen. L., O'Connor. MN., Wilson. E., Jennings. NS., Garner.
SF., Zhang. Y., Knight. CG., Dafforn. TR., Buckle. A., Ijsseldijk. MJ., De. Groot. PG., Watkins. NA., Farndale. RW., and Ouwehand. WH., Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody., Blood., 103, 903-11 (2004)
37. Takahashi. I., Saitoh. Y., Yoshida. M., Sano. H., Nakano. H., Morimoto. M., and Tamaoki. T., UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II.
Purification, physico-chemical properties, structural determination and biological activities., J Antibiot (Tokyo)., 42, 571-6 (1989)
38. Komander. D., Kular. GS., Bain. J., Elliott. M., Alessi. DR., and van. Aalten. DM., Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition., Biochem J., 375, 255-62 (2003)
39. Guentert. TW., and Oie. S., Factors influencing the apparent protein binding of quinidine., J Pharm Sci., 71, 325-8 (1982)
40. Kristensen. CB., and Gram. LF., Equilibrium dialysis for determination of protein binding or imipramine evaluation of a method., Acta Pharmacol Toxicol (Copenh)., 50, 130-6 (1982)
41. Ponganis. KV., and Stanski. DR., Factors affecting the measurement of lidocaine protein binding by equilibrium dialysis in human serum., J Pharm Sci., 74, 57-60 (1985) 42. Lund. M., Bjerrum. OJ., and Bjerrum. MJ., Structural heterogeneity of the binding sites of HSA for phenyl-groups and medium-chain fatty acids. Demonstration of equilibrium between different binding conformations., Eur J Biochem., 260, 470-6 (1999)
43. Vorum. H., and Honore. B., Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy., J Pharm Pharmacol., 48, 870-5 (1996)
44. Wilting. J., van. der. Giesen. WF., Janssen. LH., Weideman. MM., Otagiri. M., and Perrin. JH., The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis., J Biol Chem., 255, 3032-7 (1980)
45. Urien. S., Bree. F., Testa. B., and Tillement. JP., pH-dependency of basic ligand binding to alpha 1-acid glycoprotein (orosomucoid)., Biochem J., 280, 277-80 (1991)
46. Urien. S., Bree. F., Testa. B., and Tillement. JP., pH-dependence of warfarin binding to alpha 1-acid glycoprotein (orosomucoid)., Biochem J., 289, 767-70 (1993)
47. Primozic. S., and McNamara. PJ., Effect of the sialylation state of alpha 1-acid glycoprotein on propranolol binding., J Pharm Sci., 74, 473-5 (1985)
48. Herve. F., Caron. G., Duche. JC., Gaillard. P., Abd. Rahman. N., Tsantili-Kakoulidou.
A., Carrupt. PA., d'Athis. P., Tillement. JP., and Testa. B., Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant., Mol Pharmacol., 54, 129-38 (1998)
49. Herve. F., Duche. JC., and Jaurand. MC., Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma., J Chromatogr B Biomed Sci Appl., 715, 111-23 (1998)
50. Fraenkel-Conrat. H., Methods for investigating the essential groups for enzyme activity., Methods Enzymol., 4, 247-249 (1957)
51. Roosemont. JL., Reaction of histidine residues in proteins with diethylpyrocarbonate:
differential molar absorptivities and reactivities., Anal Biochem., 88, 314-20 (1978) 52. Sokolovsky. M., Riordan. JF., and Vallee. BL., Tetranitromethane. A reagent for the
nitration of tyrosyl residues in proteins., Biochemistry., 5, 3582-9 (1966)
53. Friedman. ML., Schlueter. KT., Kirley. TL., and Halsall. HB., Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents., Biochem J., 232, 863-7 (1985)
54. Bruggemann. EP., Currier. SJ., Gottesman. MM., and Pastan. I., Characterization of the azidopine and vinblastine binding site of P-glycoprotein., J Biol Chem., 267, 21020-6 (1992)
55. Greenberger. LM., Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12., J Biol Chem., 268, 11417-25 (1993)
56. Nakayama. H., Taki. M., Striessnig. J., Glossmann. H., Catterall. WA., and Kanaoka. Y., Identification of 1,4-dihydropyridine binding regions within the alpha 1 subunit of skeletal muscle Ca2+ channels by photoaffinity labeling with diazipine., Proc Natl Acad Sci USA., 88, 9203-7 (1991)
57. Kuniyasu. A., Itagaki. K., Shibano. T., Iino. M., Kraft. G., Schwartz. A., and Nakayama.
H., Photochemical identification of transmembrane segment IVS6 as the binding region of semotiadil, a new modulator for the L-type voltage-dependent Ca2+ channel., J Biol Chem., 273, 4635-41 (1998)
58. Smith. GB., and Olsen. RW., Deduction of amino acid residues in the GABA(A) receptor alpha subunits photoaffinity labeled with the benzodiazepine flunitrazepam., Neuropharmacology., 39, 55-64 (2000)
59. Duncalfe. LL., Carpenter. MR., Smillie. LB., Martin. IL., and Dunn. SM., The major site of photoaffinity labeling of the gamma-aminobutyric acid type A receptor by [3H]flunitrazepam is histidine 102 of the alpha subunit., J Biol Chem., 271, 9209-14 (1996)
60. Kurata. N., Matsushita. S., Nishi. K., Watanabe. H., Kobayashi. S., Suenaga. A., Otagiri.
M., Characterization of a binding site of UCN-01, a novel anticancer drug on alpha-acid glycoprotein., Biol Pharm Bull., 23, 893-5 (2000)
61. Katsuki. M., Chuang. VTG., Nishi. K., Suenaga. A., and Otagiri. M., Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein., Pharm Res., 21, 1648-55 (2004)
62. Urien. S., Giroud. Y., Tsai. RS., Carrupt. PA., Bree. F., Testa. B., and Tillement. JP.,
Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity., Biochem J., 306, 545-9 (1995)
63. Kopecky. V. Jr., Ettrich. R., Hofbauerova. K., and Baumruk. V., Structure of human alpha1-acid glycoprotein and its high-affinity binding site., Biochem Biophys Res Commun., 300, 41-6 (2003)
64. Zhao. B., Bower. MJ., McDevitt. PJ., Zhao. H., Davis. ST., Johanson. KO., Green. SM., Concha. NO., and Zhou. BB., Structural basis for Chk1 inhibition by UCN-01., J Biol Chem., 277, 46609-15 (2002)
65. Yamaoka. K., Tanigawara. Y., and Uno. T., A pharmacokinetic analysis program (MULTI) for microcomputer., J Pharmacobio-Dyn., 4, 879-885 (1981)
66. Fehske. KJ., Muller. WE., and Wollert. U., The modification of the lone tryptophan residue in human serum albumin by 2-hydroxy-5-nitrobenzyl bromide. Characterization of the modified protein and the binding of L-tryptophan and benzodiazepines to the tryptophan-modified albumin., Hoppe Seylers Z Physiol Chem., 359, 709-17 (1978) 67. Oka. JA., and Weigel. PH., Recycling of the asialoglycoprotein receptor in isolated rat
hepatocytes. Dissociation of internalized ligand from receptor occurs in two kinetically and thermally distinguishable compartments., J Biol Chem., 258, 10253-62 (1983) 68. Warren. L., The thiobarbituric acid assay of sialic acids., J Biol Chem., 234, 1971-5
(1959)
69. Herve. F., Duche. JC., Barre. J., Millot. MC., and Tillement. JP., pH titration curves of the desialylated human alpha 1-acid glycoprotein variants by combined isoelectrofocusing-electrophoresis: utilization in the development of a fractionation method for the protein variants by chromatography on immobilized metal affinity adsorbent., J Chromatogr., 577, 43-59 (1992)
70. Laemmli. UK., Cleavage of structural proteins during the assembly of the head of bacteriophage T4., Nature., 227, 680-5 (1970)
71. Schagger. H., and von. Jagow. G., Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa., Anal Biochem., 166, 368-79 (1987)
72. Davis. MT., and Lee. TD., Analysis of peptide mixtures by capillary high performance liquid chromatography: a practical guide to small-scale separations., Protein Sci., 1,